Zuclopenthixol acetate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413151

CAS#: 85721-05-7 (acetate)

Description: Zuclopenthixol acetate is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1962 by Lundbeck. Zuclopenthixol is the cis-isomer of clopenthixol. Zuclopenthixol is not approved for use in the United States. Zuclopenthixol has high affinity for both dopamine D1 and D2 receptors, for α1-adrenoceptors and 5-HT2 receptors but no affinity for cholinergic muscarine receptors. It has weak histamine (H1) receptor affinity and no α2-adrenoceptor blocking activity.


Chemical Structure

img
Zuclopenthixol acetate
CAS# 85721-05-7 (acetate)

Theoretical Analysis

MedKoo Cat#: 413151
Name: Zuclopenthixol acetate
CAS#: 85721-05-7 (acetate)
Chemical Formula: C24H29ClN2O2S
Exact Mass: 0.00
Molecular Weight: 445.020
Elemental Analysis: C, 64.78; H, 6.57; Cl, 7.97; N, 6.30; O, 7.19; S, 7.20

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 53772-83-1 (free base)   58045-23-1 (HCl)   85721-05-7 (acetate)   64053-00-5 (decanoate),  

Synonym: Zuclopenthixol acetate; EINECS 288-415-5; UNII-349S2ZHF05

IUPAC/Chemical Name: (Z)-4-(3-(2-Chloro-9H-thioxanthen-9-ylidene)propyl)piperazine-1-ethyl acetate

InChi Key: DFUPOTHAXAAUMS-ZTQBIIPRSA-N

InChi Code: InChI=1S/C20H21ClN2S.C4H8O2/c21-15-7-8-20-18(14-15)16(17-4-1-2-6-19(17)24-20)5-3-11-23-12-9-22-10-13-23;1-3-6-4(2)5/h1-2,4-8,14,22H,3,9-13H2;3H2,1-2H3/b16-5-;

SMILES Code: ClC1=CC(/C2=C\CCN3CCNCC3)=C(SC4=C2C=CC=C4)C=C1.CC(OCC)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 445.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.
Jayakody K, Gibson RC, Kumar A, Gunadasa S.
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD000525. doi: 10.1002/14651858.CD000525.pub3.
PMID: 22513898 Free PMC article. Review.

2. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.
Gibson RC, Fenton M, Coutinho ES, Campbell C.
Cochrane Database Syst Rev. 2004;(3):CD000525. doi:

3. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses.
Fenton M, Coutinho ES, Campbell C.
Cochrane Database Syst Rev. 2001;(3):CD000525. doi: 10.1002/14651858.CD000525.
PMID: 11686965 Updated. Review.

4. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses.
Fenton M, Coutinho ES, Campbell C.
Cochrane Database Syst Rev. 2000;(2):CD000525. doi: 10.1002/14651858.CD000525.
PMID: 10796549 Updated. Review.

5. Zuclopenthixol versus placebo for schizophrenia.
Lacey M, Jayaram MB.
Cochrane Database Syst Rev. 2015 Dec 1;(12):CD010598. doi:

6. Zuclopenthixol-acetate treatment in catatonic patients: the implication of iron metabolism.
Conca A, Bertsch E, Küng A, Waschgler R, Hrubos W, König P, Hansen M.
Eur Psychiatry. 2003 Feb;18(1):28-31. doi: 10.1016/s0924-9338(02)00008-1.
PMID: 12648893 Clinical Trial.

7. Economic evaluation of zuclopenthixol acetate compared with injectable haloperidol in schizophrenic patients with acute psychosis.
Laurier C, Kennedy W, Lachaine J, Gariepy L, Tessier G.
Clin Ther. 1997 Mar-Apr;19(2):316-29. doi: 10.1016/s0149-2918(97)80120-8.
PMID: 9152570

8. Zuclopenthixol acetate in psychiatric emergencies: looking for evidence from clinical trials.
Coutinho E, Fenton M, Adams C, Campbell C.
Schizophr Res. 2000 Dec 15;46(2-3):111-8. doi: 10.1016/s0920-9964(99)00226-1.
PMID: 11120423

9. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis.
Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ, Fensbo C, Gravem A, Pedersen V, Elgen K, Brekke B, Fredslund-Andersen K, et al.
Acta Psychiatr Scand. 1993 Jan;87(1):48-58. doi: 10.1111/j.1600-0447.1993.tb03329.x.
PMID: 8093824 Clinical Trial.

10. Zuclopenthixol acetate (Clopixol Acuphase) for rapid sedation.
Malhi GS, Holloway F, Taylor D.
Int J Psychiatry Clin Pract. 1999;3(2):135-6. doi: 10.3109/13651509909024774.
PMID: 24941096